Evidence map›Paper›PMID 39542212›Full record

Observational studyOphthalmology. Glaucoma

Enhancing Detection of Glaucoma Progression: Utility of 24-2 Visual Field Central Points vs. 10-2 Visual Fields.

Maryam Ashrafkhorasani, Sajad Besharati, Vahid Mohammadzadeh, Jane Zou, Judy Figueroa, Masood Mohammadi, Kouros Nouri-Mahdavi

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Ophthalmology. Glaucoma. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maryam AshrafkhorasaniGlaucoma Division, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Sajad BesharatiGlaucoma Division, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Vahid MohammadzadehGlaucoma Division, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California; Department of Ophthalmology, University of Louisville, Louisville, Kentucky.
Jane ZouGlaucoma Division, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Judy FigueroaGlaucoma Division, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Masood MohammadiDepartment of Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana.
Kouros Nouri-MahdaviGlaucoma Division, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California. Electronic address: nouri-mahdavi@jsei.ucla.edu.

Funding

Detection of Disease Progression in Advanced GlaucomaR01EY029792 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NOURI-MAHDAVI, KOUROS · 2020 to 2024
$1.9M
NEI NIH HHS R01 EY029792
6 · The paper itself

Abstract

purposeTo test the hypothesis that a summary index derived from the central 12 points of the 24-2 visual field (12-point mean deviation [MD12]) could provide complementary information to that provided by the 24-2 visual field (VF) mean deviation (24-2 MD).

designLongitudinal observational study.

participantsOne hundred twenty-five eyes (125 patients) with central damage or moderate to severe glaucoma from the Advanced Glaucoma Progression Study with ≥ 4 pairs of 10-2 and 24-2 Swedish Interactive Thresholding Algorithm standard VFs.

methodsBaseline 10-2 and 24-2 VF dates were within 6 months, and the remaining pairs of VF tests were done in the same session. The MD12 index was calculated by averaging total deviation values from the central 12 points of 24-2 VF. Simple linear regression of MD against time was used to estimate 24-2 MD, 10-2 MD, and MD12 rates of change (RoC). Progression at the final follow-up visit was defined as a RoC < 0 dB/year with P < 0.05 for any summary index with confirmation.

main outcome measuresProportion of progressing eyes based on 24-2 MD, 10-2 MD, and MD12 RoC.

resultsThe average (standard deviation) baseline 24-2 and 10-2 MD were -9.0 ± 6.2 and -8.5 ± 5.4 dB, respectively. The mean follow-up time was 5.7 (±1.6) years. The three summary indices were highly correlated at baseline: r = 0.62 (95% confidence interval: 0.52-0.74) between 10-2 MD and 24-2 MD, 0.84 (95% confidence interval: 0.78-0.90) between MD12 and 24-2 MD, and 0.86 (95% confidence interval: 0.80-0.92) between 10-2 MD and MD12. The corresponding correlations between RoC were weaker: r = 0.41 (95% confidence interval: 0.37-0.45), 0.80 (95% confidence interval: 0.78-0.82), and 0.49 (95% confidence interval: 0.45-0.53). Glaucoma progression was detected in 29 (23.2%), 22 (17.6%), and 23 eyes (18.4%) based on the 24-2, 10-2, and MD12 RoC, respectively; 7 eyes (9.6%) exhibited progression based on MD12 RoC and not with 24-2 MD; only 3 of these eyes progressed according to 10-2.

conclusionsMD12 RoC and detection rates have a low level of agreement with those of 10-2 and hence do not replace the need for 10-2 VF MD to monitor central damage. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Indexed as

GlaucomaIntraocular PressureVisual FieldsVisual Field TestsAgedDisease ProgressionFemaleFollow-Up StudiesHumansMaleMiddle AgedROC Curve10-2 visual field24-2GlaucomaProgressionSummary Index

Identifiers

PMID39542212
PMCPMC13364502

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.